BioCentury
ARTICLE | Company News

Ariel Pharmaceuticals, BTG deal

September 26, 2011 7:00 AM UTC

BTG granted Ariel exclusive, worldwide rights to develop and commercialize prostaglandin E2 (PGE2) receptor EP4 subtype ( Prostanoid EP4 receptor; PTGER4) antagonist AP-1531. Ariel plans to start a...